Table 1.

Patient Characteristics

Patient Characteristic	No. Patients
Age (y)
Median [range]	41 [5–59]
<20	8
20–29	4
30–39	16
40–59	33
Donor
Matched related	42
Mismatched related	8
Matched unrelated	8
Mismatched unrelated	3
Histologic Diagnosis (WHO classification)
Diffuse large B-cell	7
Mantle Cell	9
Lymphoblastic	10
Anaplastic large cell	7
Follicular	10
Transformed	11
Othera	7
Stageb
II	9
III	11
IV	26
Karnofsky Performance Status
≥ 80	50
< 80	11
Extranodal sites involved
≤ 1	51
> 1	10
LDH
Median [range]	174 [104–474]
≤ 210	39
> 210	22
Bone marrow involvementc
Yes	14
No	47
Prior chemotherapy regimens
Median [range]	2 [1–8]
1–2	32
>2	29
Response to last therapy
Complete remission	15
Partial remission	24
Stable disease	10
Refractory	12
Second-line age-adjusted IPI (sAAIPI)
Low-risk	18
Low-intermediate risk (1)	22
High-intermediate risk (2)	13
High risk (3)	8

^aDiffuse small cleaved cell (n=1), Diffuse mixed small and large cell (n=1), Small lymphocytic (n=1), HTLV-I associated Adult T cell (n=1), Angioimmunoblastic (n=1), Burkitt’s (n=1), Mycosis Fungoides (n=1);

^bFifteen patients were in CR prior to allo-HSCT – highest stage since diagnosis: stage III=9, stage IV=52;

^cBone marrow involvement at any time since diagnosis was present in 38 patients.